CA Market News
2週前
Britannia Life Sciences Announces $5.3 Million Acquisition of Commercial Equipment Loan PortfolioJune 12, 2026 7:30 AM
NewsfilePerforming Portfolio Acquired at a Discount Reflects Continued Progress in the Company's Asset-Backed Lending Strategy; Company Expects to Generate in Excess of $2 Million in Free Cash Flow Over the Coming Twelve MonthsToronto, Ontario--(Newsfile Corp. - June 12, 2026) - Britannia Life Sciences Inc. (CSE: BLAB) (the "Company" or "Britannia") is pleased to announce that it has completed a strategic investment of approximately $5.3 million in a portfolio of performing commercial equipment loans (the "Investment") on highly opportunistic terms. The Investment represents the continued execution of the Company's asset-backed lending strategy and meaningfully expands the Company's base of recurring, high-return contracted cash flow.Transaction HighlightsThe Investment is comprised of a portfolio of senior secured commercial equipment loans that are fully performing as of closing (the "Portfolio"). The Company's underwriting of the Portfolio focused on three core attributes:Conservative loan-to-value. Each underlying loan is secured by identifiable commercial equipment, and the aggregate purchase price reflects a conservative loan-to-value relative to the appraised collateral value of the Portfolio.Strong collateral and cash flow coverage. The Portfolio benefits from strong collateral coverage and contracted borrower payments that, in aggregate, provide meaningful coverage of scheduled debt service.Acquired at a discount. The Company was able to acquire the Portfolio at an opportunistic discount to face value as a result of current dislocation and repricing in segments of the non-bank commercial lending market. The Company believes that these structural conditions are creating attractive opportunities to acquire performing, well-collateralized credit assets at compelling risk-adjusted returns.Impact on Cash FlowCombined with the current income generated by the Company's existing lending operations, the Investment is expected to generate in excess of $2 million in free cash flow over the coming twelve months. This level of recurring cash flow is expected to support the further growth of the Company's lending platform and fund the Company's working capital requirements without reliance on additional financing.Alignment with the Company's Venture Builder StrategyThe Investment is consistent with the venture builder strategy outlined in the Company's recent announcement. A core principle of that strategy is the pairing of the Company's own proprietary capital alongside external capital to build and scale operating businesses, allowing the Company to establish a meaningful position while extending the reach and impact of its balance sheet.This is the same approach successfully employed in the development of Paragon Advanced Labs Inc. (TSXV: PALS), where the Company's operations expertise, key industry relationships, and proprietary capital were deployed, alongside external investment, to build and scale an independent operating platform. The additional cash flow generated by the Company's lending operations, together with its significant cash position, provides the Company with the resources to continue applying this proprietary-plus-external capital model across both its lending activities and future venture builder initiatives.Continued Progress in Asset-Backed LendingThe Investment also represents continued progress in the build-out of the Company's asset-backed lending business. The Company has spent considerable time over the past several quarters developing origination relationships, underwriting standards, and portfolio monitoring capabilities focused on secured commercial credit, with an emphasis on shorter-duration, well-collateralized assets.This opportunistic allocation is a direct result of the Company's continued diligence in the asset-backed lending space. The Company continues to pursue additional avenues to scale its lending business, including through organic origination, further opportunistic portfolio acquisitions, and strategic partnerships where attractive risk-adjusted returns can be identified.About Britannia Life Sciences Inc.Britannia Life Sciences Inc. (CSE: BLAB) is a publicly listed company pursuing a disciplined capital allocation strategy with a current focus on asset-backed lending and related credit opportunities. The Company is committed to building long-term shareholder value through recurring cash flow generation and disciplined deployment of capital.For Further InformationPeter Shippen
Chief Executive Officer
Britannia Life Sciences Inc.
Email: peter@britannia.lifeForward-Looking InformationThis news release contains "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking information includes, but is not limited to, statements regarding the expected performance of the acquired commercial equipment loan portfolio; the loan-to-value, collateral coverage, and discount characteristics of the portfolio; the Company's expectation of generating in excess of $2 million in free cash flow over the coming twelve months; the Company's cash position and ability to fund growth; the Company's venture builder strategy and its intention to continue pairing proprietary capital with external capital across its lending activities and future venture builder initiatives; and the Company's intention to continue scaling its asset-backed lending business through organic origination, additional opportunistic portfolio acquisitions, and strategic partnerships.Forward-looking information is based on assumptions and expectations of management at the date this information is given, including assumptions regarding borrower performance, the realizable value of underlying collateral, the continued availability of attractive lending and investment opportunities, prevailing conditions in non-bank commercial credit markets, and general economic and market conditions. Actual results could differ materially from those anticipated due to a number of risks and uncertainties, including credit losses, changes in interest rates, regulatory developments, and the risks described in the Company's continuous disclosure filings available under its profile at www.sedarplus.ca. The Company undertakes no obligation to update or revise any forward-looking information except as required by applicable securities law.Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301239 Original: Britannia Life Sciences Announces $5.3 Million Acquisition of Commercial Equipment Loan Portfolio
CA Market News
1月前
Britannia Life Sciences Provides Corporate UpdateMay 21, 2026 9:08 AM
NewsfileCorporate Treasury Positioned with Cash and Liquid Equity Holdings to Seed, Incubate and Accelerate New and Existing OperationsToronto, Ontario--(Newsfile Corp. - May 21, 2026) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") today provides a corporate update on its current asset position, strategic direction, and capital markets initiatives. The Board of Directors has approved a refined corporate strategy which repositions Britannia as a public market "venture builder and company accelerator." Separately, the Board has also approved the commencement of a normal course issuer bid (the "NCIB"), subject to acceptance by the Canadian Securities Exchange (the "CSE").Current Asset PositionAs of the date of this release, the Company's principal assets consist of:Cash and cash equivalents of approximately C$18 million; An evolving Asset Backed Lending Portfolio of approximately C$5 million; and262,860 common shares of Paragon Advanced Labs Inc. (TSXV: PALS) ("Paragon"), with a market value of approximately C$900,000 at the recent trading price of Paragon common shares.On a combined basis, the Company's net asset value is approximately C$23 million, or C$0.1475 per Britannia common share. The income generated from the Company's asset backed lending portfolio allows it to cover all its operating costs and generates an estimated net income of approximately $600,000 annually, or C$0.0037/share.Asset Backed LendingThe Company has continued to develop its asset backed lending expertise with the goal of using the revenue and cash flow from these operations to act as a strategic funding source for its venture builder model.The Company has terminated its previously outlined debenture offering and is seeking other avenues to scale the asset backed lending operations with alternative funding sources.Normal Course Issuer BidThe Board has approved, subject to acceptance by the CSE, the commencement of an NCIB through the facilities of the CSE and alternative Canadian trading systems. Key terms of the proposed NCIB are as follows:Maximum shares: up to 8.1 million common shares, representing approximately 5% of the Company's issued and outstanding common shares in accordance with the policies of the CSE;Duration: a twelve-month period commencing on the date the NCIB is accepted by the CSE;Purchase mechanics: purchases will be made at prevailing market prices through the facilities of the CSE and permitted alternative trading systems, in accordance with applicable rules and policies, including daily volume limitations;Funding: purchases under the NCIB will be funded from the Company's available cash resources.The Board believes that the Company's common shares have, from time to time, traded at prices that do not adequately reflect the underlying value of the Company's assets and the future prospects of its strategy. In the view of the Board, the repurchase of common shares at such prices represents an attractive use of treasury capital and is consistent with the Company's objective of maximizing long-term shareholder value.There can be no assurance as to how many common shares, if any, will ultimately be repurchased under the NCIB. All shares purchased under the NCIB will be cancelled.About Britannia Life Sciences Inc.Britannia Life Sciences Inc. (CSE: BLAB) is a Canadian public company operating as a diversified services and investment platform. The Company functions as a public-market venture builder, originating, founding, capitalizing, and operationally supporting new businesses across selected sectors, with the objective of creating long-term shareholder value through cornerstone equity positions and defined liquidity outcomes..For Further InformationPeter ShippenChief Executive OfficerBritannia Life Sciences Inc.Email: peter@britannia.lifeForward-Looking StatementsThis news release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities laws. Forward-looking statements include, without limitation, statements regarding the Company's strategic direction and its operation as a public-market venture builder and the economic prospects thereof; the composition and value of the Company's assets, including its shareholding in Paragon Advanced Labs Inc.; the Company's ability to cover all its operating costs from, and generate additional income from its asset backed lending portfolio in amounts in line with historical income; the proposed NCIB, including its acceptance by the CSE, the number of shares (if any) that may be purchased, the timing of any such purchases, and the use of treasury capital; and other initiatives the Company may pursue from time to time. Forward-looking statements are based on assumptions made by management in light of its experience and perception of historical trends, current conditions, and expected future developments, and are subject to a number of known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements, including, without limitation, regulatory acceptance, market conditions, the availability of suitable investment opportunities, and execution risk. Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable securities laws.Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298382 Original: Britannia Life Sciences Provides Corporate Update
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
ernie44
3年前
MKS420
3年前
WeedWarrior
8年前
メールアドレスで登録
